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Abstract
Background: Tissue specific promoters may be utilized for a variety of applications, including programmed gene
expression in cell types, tissues and organs of interest, for developing different cell culture models or for use in
gene therapy. We report a novel, tissue-specific promoter that was identified and engineered from the native
upstream regulatory region of the human gene NDUFV1 containing an endogenous retroviral sequence.
Results: Among seven established human cell lines and five primary cultures, this modified NDUFV1 upstream
sequence (mNUS) was active only in human undifferentiated germ-derived cells (lines Tera-1 and EP2102), where it
demonstrated high promoter activity (~twice greater than that of the SV40 early promoter, and comparable to the
routinely used cytomegaloviral promoter). To investigate the potential applicability of the mNUS promoter for
biotechnological needs, a construct carrying a recombinant cytosine deaminase (RCD) suicide gene under the
control of mNUS was tested in cell lines of different tissue origin. High cytotoxic effect of RCD with a cell-death
rate ~60% was observed only in germ-derived cells (Tera-1), whereas no effect was seen in a somatic, kidney-
derived control cell line (HEK293). In further experiments, we tested mNUS-driven expression of a hyperactive
Sleeping Beauty transposase (SB100X). The mNUS-SB100X construct mediated stable transgene insertions exclusively
in germ-derived cells, thereby providing further evidence of tissue-specificity of the mNUS promoter.
Conclusions: We conclude that mNUS may be used as an efficient promoter for tissue-specific gene expression in
human germ-derived cells in many applications. Our data also suggest that the 91 bp-long sequence located
exactly upstream NDUFV1 transcriptional start site plays a crucial role in the activity of this gene promoter in vitro
in the majority of tested cell types (10/12), and an important role - in the rest two cell lines.
Background
Tissue-specific promoters may be utilized for a variety
of applications, including programmed gene expression
in cell types, tissues and organs of interest, and for
developing different cell culture models or for use in
gene therapy. For example, one of the most promising
approaches of gene therapy is the delivery of “suicide”
genes under transcriptional control of promoters highly
active in cancer cells (e.g, [1,2]). In therapeutic con-
structs it is extremely important to precisely tune the
transcriptional activity of the gene expression system in
order to ensure the safety of a gene-therapeutic drug for
normal tissues. To reach this goal, native promoter
sequences are frequently modified by deleting or adding
different regulatory motifs, most frequently - transcrip-
tion factor recognition sites [3].
Among the suicide genes, the most efficient are those
that have a “bystander” effect, i.e. activity not only for
the cells that received the gene construct, but also for
the neighboring cells. The bystander effect is especially
valuable when the efficiency of gene delivery into the
cell nuclei is low, as it is the case for a number of
human tissues [4]. This makes it possible that even a
small number of transfected cells expressing a therapeu-
tic construct may cause massive target cell death in a
malignant tissue [5]. However, fine tuning of gene activ-
ity is more precise in binary systems that may include a
suicide gene product (an enzyme) and its chemical sub-
strate that together elicit a cytotoxic effect. In this sys-
tem, both the gene product and the substrate are
* Correspondence: bu3din@mail.ru
† Contributed equally
1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
Full list of author information is available at the end of the article
Kuzmin et al. BMC Biotechnology 2010, 10:58
http://www.biomedcentral.com/1472-6750/10/58
© 2010 Kuzmin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
harmless when present separately in the cell. However,
codelivery of the enzyme and its substrate results in
conversion of the substrate into a toxic metabolite that
kills the cell. Several, efficient binary systems have been
developed to date, for example, herpes simplex virus
thymidine kinase with gancyclovir [6], or cytosine dea-
minase with 5-fluoro cytosine [7].
In this paper we describe a novel, genetically engi-
neered, tissue-specific promoter and propose two,
related gene cassettes for generation of gene therapeutic
constructs.
Previous studies suggested that the long terminal
repeats (LTRs) of human endogenous retroviruses exhibit
significant enhancer activity in vitro [8,9]. For the HERV-
K (HML-2) elements, this effect was especially strong in
cultured human testicular germ cells, in good agreement
with numerous reports documenting high transcriptional
activities of the HERV-K (HML-2) elements in germ cell-
derived cancer tissues (e.g., [10-15]). Many HERV-K
(HML-2) genomic inserts are located in upstream regions
of genes close to transcriptional start sites, and theoreti-
cally may serve as functional enhancer elements in vivo
[12,16]. We hypothesized that removing non - HERV-K
(HML-2)-associated regulatory elements from the
upstream regions of these genes might switch their pro-
moter specificities towards relatively higher expression in
germ cells. We have tested this hypothesis on the human
gene NDUFV1 that has a HERV-K (HML-2) LTR rela-
tively close to its transcriptional start site (distance
~2.6 kb). Considering that important regulatory
sequences are frequently conserved, we removed all con-
served motifs from the NDUFV1 upstream region.
Here we show that the resulting modified NDUFV1
upstream sequence (mNUS) may serve as a strong, tis-
sue-specific promoter. On a panel of twelve human cell
lines we show that mNUS provides strong, selective
gene expression in testicular, germ-derived cells. This
specificity was further supported by a selective cytotoxic
effect of an mNUS-driven suicide gene (RCD, recombi-
nant cytosine deaminase), only in cultured germ-derived
cells. Finally, transposase expression under transcrip-
tional control of mNUS, provided selective, germ cell-
specific genomic Sleeping Beauty transposition. Our data
suggest that mNUS may be used as an efficient, tissue-
specific promoter for germ cells.
Results
Modification of NDUFV1 upstream sequence
NDUFV1 encodes the mitochondrial protein NADH
dehydrogenase ubiquinone flavoprotein 1 and is
expressed in all human tissues as a housekeeping gene
[17]. At the distance of ~2.6 kb upstream of the
NDUFV1 transcriptional start site there is a HERV-K
(HML-2) endogenous retroviral solitary LTR element.
Bioinformatical screening has revealed a highly con-
served, 91 bp-long sequence exactly upstream the
NDUFV1 transcriptional start site (Additional file 1, Fig.
S1). In order to test the possibility that removal of this
conserved sequence may alter tissue specificity of the
NDUFV1 upstream region, we have PCR-amplified and
cloned two genomic fragments, one including the whole,
3665 bp-long upstream sequence, and the other, 3574
bp-long sequence lacking the conserved region. Primary
structure of both cloned fragments was confirmed by
sequencing. The shorter sequence termed modified
NDUFV1 upstream sequence (mNUS) was further com-
pared with the native upstream region (NUS; the longer
sequence) with respect to transcriptional activity in
functional tests.
Tissue specificity of mNUS promoter
Promoter activity of mNUS was tested using the pGL3
basic vector (Promega) that includes the firefly luciferase
reporter gene, but lacks any promoter and enhancer ele-
ments. We cloned mNUS and NUS into pGL3 basic
upstream of the reporter gene. For functional tests we
chose seven established human cell lines and four pri-
mary cell cultures of different origin. Cell lines were:
Tera-1, EP2102, Tera-2 (testicular germ cells), NGP127
(neuroblastoma), HepG2 (hepatocarcinoma), A549 (lung
carcinoma) and HEK293 (transformed embryonic kidney
cells). Primary human cell cultures included macro-
phages, umbilical cord mesenchymal stem cells (UC-
MSC), placental mesenchymal stem cells (PMSC) and
bone marrow mesenchymal stem cells (BM).
NUS and mNUS promoter activities were measured
using “Dual luciferase” system in a series of transient
transfection experiments (Fig. 1). To minimize errors
caused by the differences in transfection efficiencies in
the independent replicates, reporter firefly luciferase
activity was normalized to the activity of herpes simplex
virus promoter-driven renilla luciferase expressed from
the cotransfected plasmid pRL-TK that provides rela-
tively uniform levels of renilla luciferase expression in
cell types of different origin (Additional file 2, Fig. S2).
We compared NUS/mNUS and virus SV40 promoter
activities.
The intact sequence (NUS) displayed high promoter
activity in the majority of tested cell types (Fig. 1). In
most of cell cultures (10 out of 12 lines), NUS activity
was significantly higher than that of the SV40 promoter
(Fig. 1). However, a very different pattern was observed
for the modified upstream sequence (mNUS)that
showed a sharp decrease in all cell types, except in
Tera-1 and EP2102 (Fig. 1). For example, relative to
NUS, mNUS activity has diminished ~65-fold in HepG2,
~35-, 33-, 19- fold in UC-MSC, NGP127, Tera-2, but
only about 2-fold in Tera-1 and EP2102 cells. In the
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absolute values, in Tera-1 cells mNUS activity was about
twice as high as that of the SV40 promoter, whereas for
the other cell types it was hardly detectable. These data
suggest that the 91 bp-long sequence located just
upstream of the NDUFV1 transcriptional start site plays
a key role in the activity of this gene promoter in vitro
in the majority of tested cell types. Interestingly, there
was a remarkable difference between mNUS promoter
activities in Tera-1, EP2102 and Tera-2 cells: in contrast
to high values in Tera-1 and EP2102, it was far lower in
Tera-2. Although all three cell lines have been estab-
lished from testicular germ cell tumors, Tera-1 and
EP2102 cells represent undifferentiated germ cell pre-
cursors, whereas Tera-2 cells are derived from partially
differentiated cells [18].
These results suggest that mNUS is a highly tissue-
specific promoter. Its activity is relatively high in undif-
ferentiated testicular germ cells, and negligible in all
other cell types tested. In further experiments, we aimed
to investigate the potential value of mNUS for biotech-
nological applications.
Functional tests of mNUS-RCD in suicide gene therapy
assays
In order to estimate the potential value of mNUS for
suicide gene therapy, we designed a construct having a
suicide gene under transcriptional control of mNUS
promoter. As a suicide gene, the recombinant bifunc-
tional yeast cytosine deaminase (CD) previously engi-
neered by Erbs and co-authors [19] was chosen. CD
normally converts cytosine into uracil. However, this
enzyme also deaminates the nontoxic prodrug 5-fluoro-
cytosine (5FC) to the highly toxic chemotherapeutic
drug 5-fruorouracil. The latter molecule is converted by
the cellular enzymatic machinery to 5-fluoro-UTP and
5-fluoro-dUMP. 5-fluoro-UTP is included into RNA
molecules, which results in the inhibition of the nuclear
processing of the ribosomal and mRNAs, whereas 5-
fluoro-dUMP irreversibly inhibits thymidylate synthase,
preventing DNA synthesis. Finally, CD cytotoxicity is
greatly amplified due to bystander effect [20].
Recombinant CD (RCD) was cloned into plasmid vec-
tors containing the tissue-specific mNUS or constitutive
cytomegaloviral (CMV) promoters or a vector lacking
any promoter and enhancer elements that was used as
negative control in functional tests. RCD gene activity
was pre-tested using no-RCD and CMV-RCD constructs
in Tera-1 cells, and RCD expression was visualized by
Western blot analysis. CMV promoter was chosen for
positive control experiments because it was highly active
in our tests in both Tera-1 and HEK 293 cell lines
(Additional file 3, Fig. S3).
Figure 1 Luciferase reporter assay of the promoter activities of SV40, NUS and mNUS elements in twelve human cell cultures. The
column height reflects the mean value of relative luciferase activity from at least four transfections, and error bars indicate standard error. Cell
lines were: Tera-1, EP2102, Tera-2 (testicular germ cells), NGP127 (neuroblastoma), HepG2 (hepatocarcinoma), A549 (lung carcinoma) and HEK293
(transformed embryonic kidney cells). Primary human cell cultures included macrophages, umbilical cord mesenchymal stem cells (UC-MSC),
placental mesenchymal stem cells (PMSC) and bone marrow mesenchymal stem cells (BM).
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Along with untransfected controls, part of the trans-
fected cells was exposed to 5-fluorocytosine (5FC),
another part did not receive 5FC. Forty-eight hours after
addition of 5FC, cell viability was measured using propi-
dium iodide (PI) tests. As expected, there was an overall
correlation between the RCD expression and observed
cytotoxicity (Fig. 2A). The proportion of dead cells was
almost equal for untransfected Tera-1 cells both
exposed and not exposed to 5FC, and for the no-RCD
Tera-1 transfectants (~9-10%). However, in the exposed
CMV-RCD transfectants ~65% of the cells died, as com-
pared to ~10% in unexposed CMV-RCD cells. There-
fore, in good agreement with published data [19,20],
cytotoxic activity of RCD completely depended on the
presence of 5FC in our tests. Furthermore, RCD activity
was promoter-dependent as in the promoter-less con-
struct there was no toxic effect, whereas the CMV-RCD
construct was highly toxic for the +5FC (5FC added)
cells. Importantly, in our system there was no promoter
“leakage” to produce background cytotoxicity. Finally,
5FC itself was not toxic, whereas in combination with
RCD its product was efficiently killing the cells.
Functional tests of mNUS-RCD were performed on
Tera-1 and HEK293 cells. In the previous assay, the
highest activity of mNUS-driven luciferase was observed
in germ cancer-derived cells (lines Tera-1 and EP2102;
Fig. 1), whereas reporter gene expression was signifi-
cantly lower in other cell cultures. For testing tissue-
specificity of mNUS-RCD, HEK293 cells were used as a
control as they were demonstrating the highest mNUS-
driven expression except for Tera-1 and EP2102 cells
(Fig. 1). Cells were transiently transfected with the
mNUS-RCD, positive control CMV-RCD and negative
control no-RCD expression plasmids and then grown in
+5FC medium (Fig. 2; shown for 24-hour application).
24 and 48 hours after addition of the 5FC, cell viability
was measured using the Propidium iodide (PI) and
Annexin V tests. In our experiments, both assays gave
similar results (Table 1).
For Tera-1, we observed background numbers (~9%)
of dead cells for all the transfectants grown in -5FC
medium, very similar values to negative controls grown
in the +5FC medium. In the positive controls (+5FC),
cell death rate was ~65-67%. Finally, in mNUS-RCD
transfectants (+5FC), we observed ~59-60% of dead
cells.
In HEK293, all transfectants grown in -FC conditions
and negative controls also displayed background propor-
tion of dead cells (~7-9%), in contrast to high values in
positive controls (~74-76%). In mNUS-RCD transfec-
tants (+5FC), the number of dead HEK 293 cells was
close to the background level (~8%; Table 1).
In sum, cytotoxicity assays have confirmed the high
tissue-specificity of mNUS-RCD cassette, because
cytotoxicity was strong in Tera-1 cells, but undetectable
in HEK293 cells. Accordingly, it is likely that no cyto-
toxic effect may be seen in all other above cell cultures,
as the promoter activity of mNUS was lower in them
than in HEK293.
Tissue-specific transposition of Sleeping Beauty by
mNUS-specific transposase expression
To assess the applicability of the mNUS promoter for
tissue-specific transgene integration, we employed a
transposon-based system. DNA transposons are mobile
elements capable to move in and into genomes using a
self-encoded protein termed transposase. The transpo-
sase recognizes so-called inverted terminal repeat (ITR)
sequences that flank each copy of DNA transposon, and
mediates physical excision of a transposon copy with
further re-insertion into a new location whithin the gen-
ome [21,22]. Nowadays, transposons are widely used by
researchers for stable gene delivery [23], in which trans-
gene cassettes flanked by the transposon-specific ITRs,
are mobilized and stably integrate into the genomes of
cells, in which the transposase is expressed (e.g., tran-
scribed from a cotransfected helper vector).
We used a stable gene delivery system based on the
Sleeping Beauty (SB) DNA transposon to further validate
the tissue-specific properties of the mNUS promoter.
High efficiency of its transposase, recently enhanced
more than 100-fold by directed mutagenesis [24], and
random chromosomal insertion make the SB system a
method of choice for many applications [25].
The enhanced SB transposase (SB100X) was transi-
ently expressed in transfected cells under the control of
mNUS promoter. The positive control vector had CMV
promoter-driven SB100X, whereas a promoterless
SB100X cassette served as negative control. SB100X vec-
tors were cotransfected with a plasmid harboring a pur-
omycin resistance (puro) cassette flanked by the SB
ITRs (Fig. 3). Expression of SB100X mediates high num-
ber of transposition events that result in a puromycin-
resistant phenotype of the cells. In our assay, we
cotransfected Tera-1 and HEK293 cells with the pairs of
SB100X-harboring vector plus ITR-Puro plasmid. In
HEK293 cells, the numbers of colonies seen for mNUS-
SB100X was very similar to those obtained in the nega-
tive control transfectants, suggesting lack of transposi-
tion. High colony numbers in the positive control
indicate efficient transposition (Fig. 3B). In Tera-1 cells,
the number of colonies was low in the negative control,
high in the positive control, and also high in case of
mNUS-SB100X transfectants (~80% of the positive con-
trol colony number).
These results suggest that mNUS-based constructs
may be efficiently used for the tissue-specific stable gene
delivery. This is also in line with our previous findings
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Figure 2 Effect of mNUS-RCD cassette on cell viability. Cells were transfected with no-RCD (negative control), mNUS-RCD (analyte) and CMV-
RCD (positive control) constructs and grown on 5FC-containing medium for 24 hours. Transfection efficiencies were measured using
cotransfection with GFP-encoding vector TurboGFP (Evrogen), only transfections with efficiency values 65-80% were scored. (A), representative
Western blot results with the antibodies specific to RCD and to a housekeeping protein GAPDH. (B), representative results of the propidium
iodide (PI) assay. Histograms for Tera-1 cells are shown in red, for HEK 293 - in blue. Proportions of dead cells are given in percents. (C),
representative FACS data for the Annexin V assay. Incidences of the living Tera-1 cells are shown in lower left quadrant (proportion in percents -
bottom, left), of apoptotic cells - in lower right quadrant (proportion - bottom, right), of necrotic cells - in upper right quadrant (proportion -
top, right). Overall proportions of dead cells were calculated as the total of proportions of apoptotic and necrotic cells.
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that in Tera-1 cells mNUS promoter strength is com-
parable to that of the CMV promoter.
Discussion
In this paper we report a novel tissue-specific promoter,
mNUS, that is highly active in human undifferentiated
testicular germ cancer cells (lines Tera-1 and EP2102),
but has no apparent activity in the other tested cell
types. The potential applicability of this promoter ele-
ment was illustrated in two examples.
First, we designed a suicide gene therapy cassette
including mNUS as an upstream transcriptional regula-
tory element, and the gene for recombinant cytosine
deaminase (RCD) as a cytotoxic agent. This mNUS-
RCD cassette has demonstrated strong, tissue-specific
cytotoxic effect restricted to germ cancer cells. We hope
that high tissue specificity and low background toxicity
of the mNUS-based cassette may be useful for the
design of novel efficient therapeuticals against germ cell
tumors (e.g., seminomas).
Second, the mNUS promoter was applied for generating a
tissue-specific system for stable gene delivery. The Sleeping
Beauty transposase expressed under transcriptional control
of mNUS efficiently mediated stable gene transfer into gen-
omes of germ cells, but not in somatic control cells.
The mNUS promoter element is rather large (~3.6 kb),
which may limit its usefulness. However, as we show
here it may be efficiently applied for both reporter con-
structs, gene transfer and suicide gene therapy vectors.
We hope that apart from these applications, mNUS may
be utilized as a tool for studying development, prolifera-
tion and functional analyses of germ cells and related
tissues.
Our data also indicate that the major upstream regula-
tory elements of the native NDUFV1 promoter are likely
to be concentrated within the 91 bp-long region located
just upstream the transcriptional start site. Here we pre-
sent a map of putative transcription factor binding sites
(TFBS) identified within NUS, predicted using the
TRANSFAC database (Additional file 4, Fig. S4). Indeed,
the above 91 bp-long region is enriched in putative
TFBS, as compared to the upstream sequence. The sec-
ond region where the highest concentration of TFBS
occurs is located within the endogenous retroviral
HERV-K(HML-2) LTR sequence. Therefore, the endo-
genous retroviral sequence likely plays an important role
in mNUS promoter activity. This hypothesis is consis-
tent with our further results showing that in vitro pro-
moter activity of mNUS in Tera-1 and EP2102 cell lines
was ~3- and ~4-times decreased when the HERV-K
(HML-2) LTR sequence was removed from mNUS
(unpublished data). Finally, tissue-specificity of the
mNUS promoter may be due to the presence of SRY/
SOX3 transcriptional factor recognition motifs that
account, among others, for germ cell-specific transcrip-
tional upregulation of gammaretroviruses and LINE-1
retrotransposons. Seven such motifs have been identified
within the mNUS HERV-K(HML-2) LTR, and six within
the downstream mNUS sequence (Fig. S4). Alternatively,
LTR enhancer activity at least in part may be driven by
nuclear factor OCT3/4. This protein is known as a mar-
ker of pluripotency, that plays a pivotal role in the early
stages of normal development in mammals. It was
found also to be the most informative diagnostic marker
for the early stages of malignant germ cell tumors. The
LTR contains three OCT3/4 binding motifs, and the
downstream mNUS regulatory sequence - two additional
ones. Experimental functional analysis of these sites and
further attempts to shorten the mNUS sequence will be
subject of future studies.
Conclusions
We conclude that mNUS may be used as an efficient
promoter for tissue specific gene expression in human
germ cells in various applications. Our data also suggest
that the 91 bp-long sequence located exactly upstream
NDUFV1 transcriptional start site plays a crucial role in
the activity of this gene promoter in vitro in the major-
ity of tested cell types (10/12), and an important role -
in the rest two cell lines.
Methods
Cloning of NDUFV1 upstream regions
NDUFV1 upstream region was explored using UCSC
Human Genome Browser http://genome.ucsc.edu/.
Native NDUFV1 upstream sequence (NUS) and
modified NDUFV1 upstream sequence (mNUS) were
Table 1 Cell viability tests on Tera-1 and HEK-293 cells
Experimenta Tera-1 HEK-293
PI assayb Annexin Vc PI assayb Annexin Vc
-5FC; -Transf. 9.2 ± 2.3 ND 7.7 ± 1.5 ND
-5FC; no-RCD 9.0 ± 1.7 ND 7.4 ± 1.7 ND
-5FC; mNUS-RCD 8.8 ± 2.9 ND 7.8 ± 2.1 ND
-5FC; CMV-RCD 9.9 ± 2.5 ND 8.2 ± 2.2 ND
+5FC; -Transf. 9.4 ± 2.1 10.9 ± 3.3 7.4 ± 1.8 8.7 ± 2.3
+5FC; no-RCD 9.1 ± 2.5 10.7 ± 2.6 7.7 ± 1.6 8.6 ± 2.9
+5FC; mNUS-RCD 59.5 ± 6.4 59.1 ± 3.9 7.8 ± 1.7 8.4 ± 2.8
+5FC; CMV-RCD 67.3 ± 7.5 64.9 ± 5.6 73.8 ± 11.3 75.5 ± 8.6
aCell viability tests shown on this table were done 24 hours after application
of 5FC. “-5FC” means “no 5FC was added”, “+FC” marks experiments with the
addition of 5FC to the medium. “-Transf.”, “no-RCD”, “mNUS-RCD” and “CMV-
RCD” mean “no transfection”, “transfection with no-RCD construct”,
“transfection with mNUS-RCD“ and “transfection with CMV-RCD“, accordingly.
bPropidium iodide tests were done at least in quadruplicates. The data
represent integral proportion of necrotic and apoptotic cells.
cAnnexin V assay was performed for all the experiments with the addition of
5FC to the medium. Tests were done in triplicates. The data represent integral
proportion of necrotic and apoptotic cells.
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PCR-amplified using 40 ng of human genomic DNA.
For NUS amplification, the following oligonucleotides
were used (5′-3′): NDfor, ACGCGTTGAGTATGCTG-
CAGGCTTGG; NDrev1, AGATCTCACTGAGGCTGAG-
GAACTGG. mNUS was amplified using the above
NDfor primer in pair with the primer NDrev2
(AGATCTGCTGCGCCCCTTCAACTTCGCC). PCR con-
ditions for both amplifications were as follows: 95°C - 2
min; 95°C - 25 s, 62°C - 25 s, 72°C - 4 min; 30 cycles.
PCR products (lengths 3665 and 3574 bp for NUS and
mNUS, respectively) were cloned into pGL3 basic vector
(Promega) upstream the reporter gene for Luciferase
using MluI and BglII restriction sites. Primary structure
of the cloned inserts and their 100% identity to the
reference genomic sequence (human genomic contig
NT_167190.1, positions 12676563-12680227 and
12676563-12680136, respectively) were confirmed by
sequencing.
Cell cultures
The following established human cell lines were used:
EP2102, Tera1 (testicular embryonal germ cell tumors
[26]), Tera-2 (partly differentiated testicular germ cells
with characteristics of central nervous system precursor
cells), NGP127 (neuroblastoma cells), HepG2 (hepato-
carcinoma), A549 (lung carcinoma) and HEK 293
(transformed embryonic kidney cells). All cell lines
except EP2102 were kindly provided by Dr. Sergey Ako-
pov and Dr. Eugene Kopanzev (Shemyakin-Ovchinnikov
Institute of Bioorganic Chemistry). EP2102 cells were
Figure 3 Comparison of mNUS activity in Tera-1 and HEK293 cell lines in Sleeping Beauty transposition. (A) Overall scheme of the
transposition assay. Only those cells that receive a genomic insertion of a puromycin resistance cassette may grow and form colonies when
exposed to antibiotic. In case of random, non-SB100X-mediated genomic integrations, the number of colonies is relatively low, whereas when
SB100X transposase gene is active the number of colonies is significantly higher. (B) Representative colony number screens. Average colony
numbers for each type of experiment are shown below the representative plates.
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obtained from the collection of Max Delbrück Center
for Molecular Medicine. Primary human cell cultures
were as follows: human peripheral blood macrophages,
provided by Dr. Olga Zatsepina (Shemyakin-Ovchinni-
kov Institute of Bioorganic Chemistry); umbilical cord
mesenchymal stem cells (UC-MSC), placental mesench-
ymal stem cells (PMSC) and bone marrow mesenchymal
stem cells (BM-MSC), fetal brain cells (FBC) provided
by Dr. Viktor Sorokin and Prof. Konstantin Yarygin
(Russian State Medical University). All subjects gave
consent for use of the above mentioned human cells in
this research. The cells were grown in DMEM/F12 (1:1)
medium containing 10% fetal calf serum (Invitrogen) at
37°C and 5% CO2.
Luciferase activity assay
Transfections were carried out in 24-well plates using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer recommendations. Dual luciferase system (Pro-
mega) was used for the luciferase activity screens. For
each transfection, 0.5 mcg of 10:1 mixture of the analyti-
cal plasmid (including firefly luciferase under control of
the regulatory sequence of interest) and normalization
plasmid was used. We used pRL-TK normalization vector
(Promega) including another reporter gene - Renilla reni-
formis luciferase, under control of a herpes simplex virus
thymidine kinase promoter to provide relatively uniform
levels of Renilla luciferase expression in co-transfected
cells. Prior transfections with analytical plasmids, we
have tested thymidine kinase promoter -driven Renilla
luciferase expression in normalization vector on five
human cell cultures. Renilla luciferase activity was mea-
sured in the cell cultures Tera-1, NGP127, HepG2, A549
and HEK293 transfected with pRL-TK normalization
vector. The luciferase activity was scored only for the
experiments with transfection efficiencies 65-70%. Trans-
fection efficiencies were measured by the GFP fluores-
cence when cotransfecting pRL-TK (Promega) with
pTurbo-GFP plasmid (Evrogen). Our results confirm the
data from Promega dual luciferase manual that pRL-TK
may serve as an efficient normalization vector (Fig. S2).
Analytical plasmids based on pGL3 vector (Promega)
had the following regulatory sequences: cloned NUS or
mNUS, or SV40 early promoter. 24-Hours after trans-
fection, cells were lysed and the activities of Renilla and
firefly luciferases were measured using Dual-Luciferase
Reporter Assay System (Promega) using luminometer
«GENios Pro» (Tecan). Plasmid pRL-TK was used in all
experiments as the internal control to minimize errors
caused by the differences in transfection efficiencies in
independant replicates. The obtained values for the fire-
fly luciferase were normalized to the values for the
Renilla luciferase. Each transfection experiment was
done at least in quadruplicate.
Cloning of the gene for recombinant cytosine deaminase
Bifunctional recombinant cytosine deaminase (RCD)
termed “SuperCD suicide fusion gene” in previous report
[20] was generated according to the published protocol.
Bifunctional RCD gene was cloned into the plasmids
pCI and pGL3 basic (Promega) linearized by NotI-SalI.
This resulted in plasmids carrying gene RCD either
under the control of standard cytomegaloviral (CMV)
promoter (pCI-CMV-RCD) or without any upstream
regulatory elements (pGL3-no-RCD). mNUS fragment
was cloned into pGL3-no-RCD using HindIII and NotI
restriction sites. RCD identity in all constructs was con-
firmed by complete sequencing.
Western blot analysis
Cells were lysed in SDS-containing sample buffer.
Lysates were separated in 10% SDS-PAGE and trans-
ferred to PVDF membranes. Polyclonal sheep antibody
against a fragment of RCD molecule (Abcam, USA) was
used to detect RCD expression. For control experiments,
monoclonal anti-GAPDH antibodies (Sigma) were used.
Immunoreactive bands were visualized using anti-sheep
secondary goat IgG-horseradish peroxidase conjugate
(Promega, USA) and ECL detection reagents (Biorad,
Russia).
Cell viability tests
Cells were transfected in 6-well plates with 10:1 mixture
of the RCD-containing vector and pTurbo-GFP (Evro-
gen) using Lipofectamine 2000 (Invitrogen) according to
the manufacturer recommendations. pTurbo-GFP served
as normalization plasmid carrying GFP gene to estimate
transfection efficiencies (only transfections with the effi-
ciency values 65-80% were scored). Approximately 12
hours after transfections, 500 μM 5FC (5-fluoro cyto-
sine) containing medium was added to the cells (this
5FC concentration was reported to be the optimum for
RCD assays [19,20]). 5-FC was purchased from Sigma
(St. Louis, MO). Viable cells were counted 24 hours and
48 hours after addition of the 5FC. Each experiment
was done in quadruplicate for the PI assay and in three
replicas - for the Annexin V test. Propidium iodide
assay with subsequent FACS data analysis were per-
formed according to the standard protocol (e.g., as
described in [27,28]). Annexin V assay and flow cyto-
metric quantization of dead cells were carried out using
the Annexin V kit (Caltag Laboratories) according to
the manufacturers’ protocol using Coulter EPICS XL
flow cytometer (Beckman Coulter).
Transposition assay
Cells were split ~3 days before transfection and reached
between 70-100% confluency. Transfections were done
using Unifectin 2000 and FuGENE (Roche) transfection
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reagents according to the manufacturer recommenda-
tions. For transfections, the following plasmid vectors
were used: pT2B/puro including puromycin resistance
gene under control of SV40 promoter flanked by the
Sleeping Beauty inverted repeats; CMV-SB100X vector
harboring enhanced Sleeping Beauty transposase gene
under control of CMV promoter (courtesy of Dr. Lajos
Mates, Max-Delbruck Center for Molecular Medicine,
Berlin, Germany); no-SB100X vector without promoter
sequence, mNUS-SB100X vector with mNUS promoter
placed upstream of the SB100X gene, and TurboGFP
vector (Evrogen) including GFP gene. Transfection effi-
ciency was assessed by GFP fluorescence. The following
vector combinations were used for transposition assays:
a) pT2B/puro alone, b) pT2B/puro + no-SB100X vector,
c) pT2B/puro + CMV-SB100X, d) pT2B/puro + mNUS-
SB100X. After transfections, cells were incubated at
37C, 5% CO2 for 48 hours. The medium was then
removed and the cells were washed with PBS, followed
by 1-minute trypsinization, stopped by the addition of
500 ul of serum-containing cell culture media to each
well. Different volumes of cells mixture (50%, 20% and
10%) were plated out on 10 cm Petri dishes for further
puromycin selection (~7 days). 10 ml of puromycin
-containing medium were added to each dish. We chan-
ged medium every two days until selection was complete
and distinct colonies formed (2-3 mm diameter). To
stain the colonies, the medium was aspirated and plates
were washed with PBS. Each plate was fixed in 10% for-
maldehyde in PBS and was incubated for 20 min at
room temperature under chemical fume. The fixing
solution was then removed and plates were washed
twice with 10 ml of PBS. 5 ml of staining solution (0,5%
methylene blue in PBS) was added and plates were incu-
bated for 30 min or more. The dye was further removed
and plates were washed in bucket of cold water. The
plates were allowed to dry, be photographed and ana-
lyzed. Transposition efficiency was determined as the
ratio of colonies formed in the presence of transposase
versus colony numbers in the absence of transposase
formed due to random integration of antibiotic resis-
tance cassette.
Additional material
Additional file 1: Figure S1: Schematic representation of NDUFV1
upstream region. 3665 bp-long NUS sequence contains highly
conserved 91 bp-long genomic fragment located exactly upstream
NDUFV1 transcriptional start site. At the 5’ terminus of NUS there is an
insert of HERV-K (HML-2) solitary LTR.
Additional file 2: Figure S2: Comparison of herpes virus thymidine
kinase promoter - driven renilla luciferase activities in cell lines
Tera-1, NGP127, HepG2, A549 and HEK293. The column height
reflects the mean value of detected luciferase activity from at least six
transfection experiments, and error bars indicate the value of a standard
error. Each experiment was made at least in quadruplicate.
Additional file 3: Figure S3: Comparison of mNUS and CMV
promoter activities in cell lines Tera-1 and HEK293. The column
height reflects the mean value of relative luciferase activity from at least
four transfections, and error bars indicate the value of a standard error.
Additional file 4: Figure S4: Schematic map of the putative
transcriptional factor binding sites within the 3665 bp-long entire
NUS region. HERV-K(HML-2) LTR sequence and 91 bp-long deletion are
shown by magenta boxes. Signs above/below represent putative
transcription factor binding sites identified in the sense/antisense
orientations, respectively. Large red circle represent putative SRY/SOX3
binding site perfectly matching the consensus sequence (ACAAAACA),
small circles - sites with single nucleotide mismatches. The detailed data
on transcriptional factor binding sites is presented on the additional
table 1.
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